Article

AAO makes case for OPT for Medicare patients

Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.